Compare INTT & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | ADAG |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 146.3M |
| IPO Year | 1997 | 2020 |
| Metric | INTT | ADAG |
|---|---|---|
| Price | $14.30 | $4.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $13.50 | $8.00 |
| AVG Volume (30 Days) | 159.9K | ★ 227.3K |
| Earning Date | 05-01-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,801,000.00 | N/A |
| Revenue This Year | $13.07 | $3,688.61 |
| Revenue Next Year | $6.52 | $17.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 66.06 | N/A |
| 52 Week Low | $5.24 | $1.33 |
| 52 Week High | $15.66 | $4.58 |
| Indicator | INTT | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 64.34 | 62.98 |
| Support Level | $7.21 | $1.69 |
| Resistance Level | $15.01 | $4.58 |
| Average True Range (ATR) | 0.89 | 0.50 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 53.54 | 70.04 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.